Ultragenyx drug apazunersen misses main goal in late-stage trial
Ultragenyx Pharmaceutical said its experimental apazunersen for Angelman syndrome did not meet the main goal in a late-stage trial, sending shares down 40% in after-hours trading.
Ultragenyx Pharmaceutical said on Wednesday that its experimental drug apazunersen did not meet the main goal in a late-stage trial for Angelman syndrome, a rare genetic neurodevelopmental disorder. The company’s shares fell 40% in aftermarket trading.